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Abstract
OBJECTIVE—To estimate the independent effect of gestational impaired glucose tolerance,
defined as a single abnormal oral glucose tolerance test (OGTT) value, on metabolic dysfunction
at 3 years postpartum.
METHODS—We used multiple linear regression to measure associations between glucose testing
during pregnancy and metabolic markers at 3 years postpartum in Project Viva, a prospective
cohort study of maternal and infant health. We compared metabolic measures at 3 years
postpartum among four groups: normal glucose challenge test (less than 140 mg/dL, n=461);
abnormal glucose challenge test but normal glucose tolerance test (GTT) (n=39); impaired glucose
tolerance (IGT) (a single abnormal GTT value, n=21); and gestational diabetes mellitus (GDM)
(n=16).
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RESULTS—Adjusting for age, race, parity, parental history of diabetes, and maternal BMI at 3
years postpartum, we found women with GDM had lower adiponectin (11.2 ng/mL vs. 20.7 ng/
mL) and higher homeostatic model assessment – insulin resistance (3.1 vs. 1.3) and waist
circumference (91.3 cm vs. 86.2 cm) compared with women with IGT or normal glucose
tolerance. Women in both the IGT and GDM groups had lower high-density lipoprotein (GDM:
44.7 mg/dL; IGT: 45.4/dL vs normal glucose tolerance 55.8 mg/dL) and higher triglycerides
(GDM: 136.1 mg/dL; IGT: 140.1 mg/dL, vs. normal glucose tolerance: 78.3), compared with
women in the normal glucose tolerance group. We found the highest values for Hemoglobin A1c
(GDM: 5.1%; IGT 5.3%, normal glucose tolerance 5.1%) and high-sensitivity c reactive protein
(GDM 1.4 mg/dL IGT: 2.2 mg/dL; NGT 1.0 mg/dL) among women with IGT.
CONCLUSION—GDM and IGT during pregnancy are associated with persistent metabolic
dysfunction at 3 years postpartum, independent of other clinical risk factors.
Introduction
Metabolic dysfunction causes substantial morbidity and mortality among women. Among
women, pregnancy complications predict metabolic disease risk. Women with gestational
diabetes (GDM) have an 17 to 63% risk of developing type 2 diabetes within 5 to 16 years
of the index pregnancy(1), and recent studies have linked a history of gestational diabetes
with cardiovascular risk(2, 3).
The diagnosis of GDM presumes a threshold value above which women are at increased risk
of pregnancy complications; however, recent work shows that adverse pregnancy outcomes
rise continuously with increasing fasting glucose values(4). Maternal metabolic risk may
similarly rise with glucose values. Indeed, recent studies have linked gestational impaired
glucose tolerance with subsequent diabetes and cardiovascular disease risk(3, 5–9).
However, it is not known whether impaired glucose tolerance during pregnancy predicts
metabolic dysfunction independent of clinical risk factors such as body mass index and
family history.
The aim of our study was to determine whether a history of GDM or gestational impaired
glucose tolerance (IGT) is predictive of maternal metabolic dysfunction, independent of
recognized clinical risk factors. We hypothesized that we would find a monotonic
relationship between degree of gestational glucose tolerance and metabolic dysfunction at 3
years postpartum. To test this hypothesis, we compared measures of metabolic dysfunction
at 3 years postpartum among women with normal glucose tolerance (NGT), abnormal
glucose loading test results but normal GTT values, gestational impaired glucose tolerance
(IGT), or GDM, in Project Viva, a prospective cohort study of maternal and infant health.
Materials and Methods
We performed an unplanned secondary analysis of participants in Project Viva, a
longitudinal cohort study of maternal and child health(10). Women were recruited for
Project Viva at their first prenatal visit at one of eight obstetrical offices of a multispecialty
group practice in Eastern Massachusetts from 1999 to 2002. To be eligible for the study,
potential participants were required to be fluent in English, <22 weeks gestation at study
entry, and have a singleton pregnancy All participants provided written informed consent,
and the Institutional Review Board of Harvard Pilgrim Health Care approved all procedures.
Assessment of gestational glucose tolerance
Obstetrical care providers assessed gestational glucose tolerance among women in our
cohort according to the following guidelines: At 26 to 28 weeks’ gestation, all mothers
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underwent a non-fasting 50g oral glucose challenge test (GCT). Women with a result of 140
mg/dL or higher underwent a 100g oral glucose tolerance test (OGTT), administered the
morning after an overnight fast. Normal results were defined by Carpenter-Coustan criteria:
fasting <95 mg/dL, 1 hour <180 mg/dL, 2 hour < 155 mg/dL, 3 hour < 140 mg/dL.
Gestational glucose tolerance was categorized as normal (GLT < 140 mg/dL), Abnormal
GLT, normal GTT (GLT >=140 mg/dL, GTT with no abnormal results), gestational
impaired glucose tolerance (IGT) (GLT >=140 mg/dL, GTT with only 1 abnormal result) (8,
11), or gestational diabetes (GLT >=140 and GTT with 2 or more abnormal results).
Assessment of metabolic parameters at 3 years postpartum
Women returned at 3 years postpartum for a physical examination that included
anthropometric measurements and a blood sample. Methodology for anthropometric
measures has been previously described elsewhere(12). We tested all blood samples
(N=537) for HbA1c, sex hormone binding globulin (SHBG), C-reactive protein (CRP), and
the adipokines leptin(13) and adiponectin(14). We identified as fasting those participants
who did not eat or drink anything other than water for 8 hours before blood samples were
obtained (N=166). We tested fasting blood samples for insulin, glucose, total cholesterol,
LDL cholesterol, HDL cholesterol, triglycerides, IL 6, ghrelin(15 ) and PYY(16). When we
compared women who provided fasting samples with those who provided non-fasting
samples, we found no differences in age, race, parity, family history of DM, gestational
glucose tolerance, or in any outcome variables measured in both fasting and non-fasting
participants. Laboratory methods for assessment of metabolic markers in this study have
been previously described (12, 17).
Study covariates
Participants reported sociodemographic variables including parity, race/ethnicity, and
personal history of type 1 or type 2 diabetes at the initial study visit during prenatal care.
They reported parental history of type 2 diabetes at three-year follow-up visit. Women
missing data on study covariates were excluded.
Data Analysis
We used analysis of variance and chi square tests to measure bivariate associations between
sociodemographic characteristics and gestational glucose tolerance. We used multiple linear
regression to model the relation between gestational glucose tolerance category and
metabolic markers at three-years. Because BMI may have a non-linear association with
metabolic markers, we used linear, quadratic and 3-knot cubic spline models(18) to adjust
for maternal BMI 3 years postpartum, retaining the more complex model if the log
likelihood ratio test p value was < 0.05. Because inclusion of quadratic and 3-knot quadratic
spline terms did not improve model fit, we modeled BMI as a linear variable. We further
adjusted for maternal age, race, parity, and parental history of type 2 diabetes to ascertain
the predictive role of gestational glucose tolerance independent of clinical risk factors for
metabolic disease. Adjustment for breastfeeding duration and weight change from pre-
pregnancy to the three-year visit did not materially change our results, and they were
therefore excluded from our model.
The Sharpiro-Wilk test and visual inspection of regression residuals suggested that
normality should not be assumed in several cases. Log transformation of HOMA-IR, insulin,
sex hormone binding globulin, triglycerides, C-reactive protein and IL6 improved normality
of regression residuals. We present p values for the partial F test to assess the joint null
hypothesis of equality across all of the glucose tolerance categories(19).
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To facilitate interpretation of both the magnitude and clinical significance of differences
among gestational glucose tolerance groups, we present results as predicted means and 95%
confidence intervals for the mean. We present both unadjusted mean values and adjusted
predicted mean values for participants of average postpartum BMI (26.2) who were white,
age 35 to <40, had two children, and had no parental history of type 2 diabetes.
Data analyses were performed using SAS 9.2. Two-tailed P values < 0.05 were considered
statistically significant.
Results
Of 5055 women screened for Project Viva, 4208 were eligible, and 2670 enrolled (Figure 1).
Among the 2128 Project Viva participants who gave birth, 1579 met criteria for a three-year
follow-up examination with their children by virtue of completing a pregnancy dietary
questionnaire and contenting for child follow-up. Of these women, 611 met criteria for the
current analysis because they attended the three-year visit, had not delivered another child
since the birth of the index child three-years previously, denied a diagnosis of type 1 or type
2 diabetes early in the index pregnancy and provided a blood sample. We excluded women
with missing data for three-year lab results (n=25), breastfeeding duration at 1 year (n=8),
BMI at 3 years postpartum (n=14), or gestational glucose tolerance (n=27), leaving 537
women for analysis. At this three-year visit, 166 women provided a fasting blood sample.
Glucose challenge test results were normal for 85.9% (N=461, 95%CI 82.9–88.8%) of
women in our cohort. Among the 76 women with a GCT >=140, 39 had all normal values
on the 100g GTT, 21 had one abnormal value (IGT), and 16 met the diagnostic criteria for
GDM. Maternal age, parity, body mass index at 3 years postpartum, and race were similar
among the glucose tolerance groups. Women with a parental history of type 2 diabetes were
more likely to have had GDM (Table 1).
Most women in our cohort gained weight from prior to the index pregnancy to the three-year
visit: the median weight gain was 2.2 kg (Interquartile range -0.4 to 5.3 kg), and 26.5%
(95%CI 22.8–30.4%) of women had gained 5 kg or more during this interval. Most
participants had normal glucose tolerance at 3 years postpartum by ADA criteria(20).
Among 535 women for whom HbA1C was obtained, 14 were at increased risk of diabetes
(A1C 5.7–6.4%) and one, with an A1C of 6.58%, met criteria for ADA diabetes (A1C
≥6.5%). In addition, one participant self-reported a diagnosis of type 2 diabetes. Among 164
women for whom fasting glucose was obtained, 2 had impaired fasting glucose (FPG 100–
125 mg/dl) and none met criteria for diabetes (FPG > 126 mg/dl).
As we hypothesized, women with both IGT and GDM had more adverse metabolic profiles
than women with normal GCT results or with abnormal GCT but normal values on the GTT.
These patterns were similar in unadjusted models and in models adjusted for BMI at 3 years
postpartum, parity, age, self-reported race and parental history of diabetes (Tables 2, 3 and
4). Women with GDM had lower adiponectin and higher HOMA-IR and waist
circumference compared with women with IGT or normal glucose tolerance (Figure 2a,
HOMA-IR GDM: 2.7 vs. NGT:1.3; adiponectin GDM 13.1 ng/mLvs. NGT 21.2 ng/mL;
waist circumference GDM 91.3 cm vs. NGT 86.2 cm; partial F test p < 0.05 for all models).
Women in both the IGT and GDM groups had lower HDL and higher triglycerides,
compared with women in the NGT group (Figure 2b: HDL GDM: 44.7 mg/dL; IGT: 45.4
mg/dL vs NGT 55.8 mg/dL, partial F test p=0.07; triglycerides GDM: 136.1 mg/dL; IGT:
140.1 mg/dL, vs. NGT: 78.3 mg/dL; partial F test p<0.01). We had hypothesized that we
would find a monotonic association between metabolic dysfunction and degree of glucose
intolerance; however, we found the highest values for Hemoglobin A1c and CRP among
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women with IGT (Figure 2c: Hemoglobin A1c GDM: 5.1%; IGT 5.3%, NGT 5.1%, partial F
test p<0.01; hsCRP GDM 1.4 mg/dL IGT: 2.2 mg/dL; normal 1.0 mg/dL, partial F test
p<0.01). We found no pattern of association between gestational glucose tolerance category
and sex hormone binding globulin, total cholesterol, fasting IL6, leptin, ghrelin or PYY
(Tables 2 and 3).
Discussion
In this community-based prospective cohort study, we found that both gestational diabetes
and gestational impaired glucose tolerance were associated with an adverse metabolic
profile at 3 years postpartum, independent of body mass index and parental history of
diabetes.
Strengths of our study include its prospective assessment of gestational glucose tolerance
and standardized assessment of three-year outcomes. Nevertheless, our results must be
interpreted within the context of the study design. Our population was healthy, resulting in
low rates of gestational diabetes and impaired glucose tolerance. Among the 91 women ages
30–39 for whom we had data on waist circumference, blood pressure, serum lipids and
glucose, only 5 (5.5%, 95% CI 1.8–12.4%) met criteria for the metabolic syndrome,
compared with 15% of women in this age range in the general US population(21). In
addition, the number of participants with fasting blood samples limited power to detect
subtle differences among glucose tolerance groups, and we were not able to define
metabolic syndrome in the full cohort. Further studies in larger populations will be needed to
validate our findings. Nevertheless, our study size is comparable to several other studies that
have assessed metabolic markers among postpartum women with a history of GDM(2, 22).
We did not measure post-glucose load insulin or glucose in our population, and therefore we
were unable to compare indices of glycemia, insulin sensitivity and beta-cell function.
Nevertheless, our study included postpartum measures of adiponectin, which is highly
correlated with beta cell dysfunction during pregnancy(23) and with 2-h post OGTT in the
postpartum period(24).
Our results confirm and extend earlier work linking gestational glucose tolerance with an
adverse maternal metabolic profile in later life. Several authors have reported an increased
risk of impaired glucose tolerance and type 2 diabetes among women with abnormal glucose
screening results in pregnancy in the setting of both normal OGTT(7) and one abnormal
GTT result (5, 6, 9, 25). Moreover, both IGT and GDM have been associated with the
metabolic syndrome at 3 months postpartum(8). Other authors have reported associations
between GDM and markers of metabolic dysfunction after pregnancy. At a mean of 2 years
postpartum, Costacou et al reported adverse associations between history of GDM (N=22)
and waist circumference, hemoglobin A1c, and HOMA-IR, compared with women without
a history of pregnancy complications (N=29)(22). Heitritter et al similarly compared women
with a GDM history (N=23) with normal controls (N=23) at a mean of 4 years postpartum.
Women in the GDM group had higher diastolic blood pressure, mean arterial pressure, heart
rate, fasting glucose, HOMA, triglycerides, CRP, IL-6, and PAI-1 and lower adiponectin
than women in the control group.
No studies to our knowledge have measured associations between IGT and LDL,
inflammatory markers or adipokines, or with other metabolic markers beyond 3 months
postpartum. We found that women with impaired glucose tolerance during pregnancy had
elevations of triglycerides, hemoglobin A1c and CRP, as well as lower HDL, after
adjustment for current body mass index and parental history of diabetes. Women with a
history of GDM had triglyceride and HDL levels that were similar to those with IGT, but
they had higher HOMA-IR and waist circumference, as well as lower adiponectin levels.
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These adverse profiles of intermediate markers among women with pregnancy dysglycemia
imply increased risk for cardiovascular disease, which is consistent with findings in a recent
population-based cohort study (3). In that study, compared with women who did not
undergo glucose tolerance testing during pregnancy and therefore were presumed to have
had normal glucose screening test results, women with both IGT and GDM were more likely
to experience cardiovascular events (IGT OR 1.19, 95% CI 1.02–1.39; GDM OR 1.66, 95%
CI 1.30–2.13).
Compared with women with normal glucose testing during pregnancy, we found that women
with a history of gestational glucose intolerance had unfavorable markers of glucose and
lipid homeostasis and inflammation. These findings persisted with adjustment for current
body mass index, suggesting that normal or overweight women with a history of IGT may
be at risk for metabolic dysfunction at 3 years postpartum. These women may therefore
benefit from dietary changes, physical activity, and/or screening for metabolic syndrome.
Current guidelines recommend screening women with a history of GDM for type 2
diabetes(26, 27).
In conclusion, in a prospective study of maternal and infant health, we found that maternal
gestational glucose intolerance and gestational diabetes were both associated with adverse
metabolic profile at 3 years postpartum, independent of other clinical risk factors.
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Flow of patients through the current study, which is a secondary analysis of Project Viva, a
longitudinal study of maternal and child health. *Eligibility requirements included singleton
gestation, ability to answer questions in English, plans to remain in the area through
delivery, and gestational age less than 22 weeks at initial prenatal clinical appointment.
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Mean predicted values for a white participant between 35 and less than 40 years of age with
a body mass index (BMI) of 26.2 (the study population mean), who has two children and no
parental history of diabetes. P-values on graph are for partial F test. The figure shows
adverse metabolic markers that differ with gestational diabetes mellitus (GDM) alone
(column A), both gestational impaired glucose tolerance and GDM (column B), or
gestational impaired glucose tolerance alone (column C). In each graph’s x-axis, A, B, C,
and D represent the following groups: Group A, 50-g screen less than 140 mg/dL; B, 50-g
screen 140 mg/dL or more with normal oral glucose tolerance test (OGTT); C, 50-g 140 mg/
dL or more with one abnormal OGTT value; D, gestational diabetes mellitus (GDM: two or
more abnormal OGTT values). Predicted mean, 95% confidence limit of the mean, adjusted
for BMI, age, race, parity, and parental history of diabetes mellitus. *P<.05 compared with
normal glucose tolerance group.
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